Krystal Biotech, Inc. to Post FY2025 Earnings of $8.69 Per Share, Chardan Capital Forecasts (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Krystal Biotech in a research report issued to clients and investors on Tuesday, August 6th. Chardan Capital analyst Y. Livshits anticipates that the company will post earnings of $8.69 per share for the year. Chardan Capital has a “Buy” rating and a $208.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.00 per share.

Other equities research analysts have also issued reports about the stock. Stifel Nicolaus reissued a “buy” rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a research note on Monday, August 5th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a report on Tuesday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.63.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded up $1.80 during midday trading on Thursday, hitting $182.17. 144,558 shares of the company’s stock traded hands, compared to its average volume of 379,286. The firm has a fifty day moving average of $187.07 and a 200 day moving average of $165.08. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of 97.42 and a beta of 0.84. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. The company’s revenue for the quarter was up 70283900.0% on a year-over-year basis. During the same period last year, the firm posted ($1.25) EPS.

Institutional Trading of Krystal Biotech

A number of hedge funds have recently bought and sold shares of KRYS. Jamison Private Wealth Management Inc. acquired a new stake in Krystal Biotech during the 2nd quarter worth about $28,000. GAMMA Investing LLC boosted its position in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares during the last quarter. Key Financial Inc acquired a new position in Krystal Biotech in the 2nd quarter worth approximately $28,000. Blue Trust Inc. raised its position in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Krystal Biotech during the 2nd quarter valued at approximately $71,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In related news, Director Julian S. Gangolli sold 20,000 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Julian S. Gangolli sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The disclosure for this sale can be found here. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).